ABCG2 and colorectal carcinoma: In conclusion, ML210 can sensitize ABCB1-overexpressing multidrug-resistant colorectal cancer cells to ABCB1-substrate chemotherapeutic agents, indicating that ML210 is a promising ABCB1 inhibitor capable of antagonizing ABCB1- not ABCG2-mediated MDR in CRC.